Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2025-12-24 Transaction in Own Shar…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Transaction in Own Shares Classification · 1% confidence The document is a 'Form F-3 Registration Statement' filed with the U.S. Securities and Exchange Commission (SEC) by Enlivex Therapeutics Ltd. It is a preliminary prospectus for the resale of ordinary shares by selling shareholders. According to the filing definitions, documents related to the registration of securities for public offering or resale (such as Form F-3) fall under the 'POS' (Post-effective/Registration) category, as they relate to the issuance or registration of shares.
2025-12-24 English
Other Report or Announcement
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing from Enlivex Therapeutics Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on *FROM F-3*' and provides a reference to an attached PDF file. According to the 'Menu vs Meal' rule, a short document that announces the publication or attachment of another report is classified as a Report Publication Announcement (RPA).
2025-12-24 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document contains a proxy voting card with specific proposals (e.g., amendments to Articles of Association, board classification, executive compensation, and reverse share split). This is a standard form used to solicit shareholder votes for an upcoming meeting, which falls under the definition of a Proxy Solicitation & Information Statement.
2025-12-19 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains a 'Notice of Extraordinary General Meeting of Shareholders' and a 'Proxy Statement' detailing proposals for shareholder voting (e.g., name change, board classification, reverse share split, and executive compensation). Since the document provides the full proxy materials and solicitation information for an upcoming meeting rather than just an announcement of the report's availability, it is classified as a Proxy Solicitation & Information Statement.
2025-12-19 English
Immediate Report of Meeting
AGM Information Classification · 1% confidence The document is an official 'Immediate Report of Meeting' filed with the Israel Securities Authority (MAGNA system). It details the convening of an extraordinary meeting, including the date, time, location, and specific agenda items (such as amendments to Articles of Association, indemnification agreements, and a reverse share split). Because this document provides the formal notice, agenda, and proxy information for an upcoming shareholder meeting, it is classified as a Proxy Solicitation & Information Statement.
2025-12-19 English
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It serves as a regulatory filing to announce an upcoming virtual fireside chat regarding the company's digital asset strategy and clinical development. While it contains a press release, the document itself is a standard SEC 6-K filing used by foreign private issuers to disclose material information. Since it does not fit into specific categories like 'Earnings Release' (it is an event announcement) or 'Investor Presentation' (it is a notice of a future event), it falls under the general regulatory filing category.
2025-12-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.